Filter By:

Article Type
  • The Nature Cancer editors share their thoughts on the highs (and some of the lows) of 2022.

    • Lisa Hoffman-Haas
    • Ioanna Pavlaki
    • Alexia-Ileana Zaromytidou
  • Twelve early career investigators share experiences from the process of starting their laboratories throughout the past year, and reflect on the challenges faced and the opportunities seized.

    • Mautin Barry-Hundeyin
    • Jian Carrot-Zhang
    • Ying Zhang
  • Tumor mutational burden (TMB) has received significant attention within ongoing pursuits of biomarkers of response to immune checkpoint inhibitors, and notably received FDA approval as a companion diagnostic biomarker for pembrolizumab. Here, four experts discuss the utility, challenges, and open questions surrounding TMB in the context of cancer immunotherapy.

    • Valsamo Anagnostou
    • Alberto Bardelli
    • Samra Turajlic
  • Twelve early-career investigators share their thoughts on the challenges faced by their teams and communities during the past year, and look ahead to new opportunities for 2022.

    • Leila Akkari
    • Stacey D. Finley
    • Meng Michelle Xu
  • Filtered through the analytical power of artificial intelligence, the wealth of available biomedical data promises to revolutionize cancer research, diagnosis and care. In this Viewpoint, six experts discuss some of the challenges, exciting developments and future questions arising at the interface of machine learning and oncology.

    • Olga Troyanskaya
    • Zlatko Trajanoski
    • Nuria Oliver
  • Cancer research in recent years has been marked by significant developments in understanding disease biology and foundational discoveries that have changed clinical practice. Ten cancer researchers take stock of the field, the advances that excite them, key outstanding questions and breakthroughs they anticipate looking forward.

    • René Bernards
    • Elizabeth Jaffee
    • Zemin Zhang